↓ Skip to main content

Gemcitabine for unresectable, locally advanced or metastatic bladder cancer

Overview of attention for article published in Cochrane database of systematic reviews, April 2011
Altmetric Badge

Mentioned by

facebook
1 Facebook page

Citations

dimensions_citation
16 Dimensions

Readers on

mendeley
91 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Gemcitabine for unresectable, locally advanced or metastatic bladder cancer
Published in
Cochrane database of systematic reviews, April 2011
DOI 10.1002/14651858.cd008976.pub2
Pubmed ID
Authors

Mike Shelley, Anne Cleves, Timothy J Wilt, Malcolm Mason

Abstract

The prognosis for unresectable, locally advanced or metastatic transitional cell carcinoma of the bladder is poor with most patients succumbing to their disease within 2 to 3 years. Clinical management at this stage of the disease is palliative with systemic chemotherapy the main treatment of choice. A number of cytotoxic agents have shown activity in metastatic disease including cisplatin, methotrexate, doxorubicin and vinblastine. However, response rates still need improving and toxicities may sometimes be severe, and so the search for newer agents with improved benefit-to-risk ratios is constantly being pursued. One such agent that shows promise is gemcitabine.

Mendeley readers

The data shown below were compiled from readership statistics for 91 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 1%
Spain 1 1%
Switzerland 1 1%
Unknown 88 97%

Demographic breakdown

Readers by professional status Count As %
Student > Master 16 18%
Student > Ph. D. Student 12 13%
Student > Bachelor 10 11%
Researcher 9 10%
Student > Doctoral Student 7 8%
Other 22 24%
Unknown 15 16%
Readers by discipline Count As %
Medicine and Dentistry 48 53%
Nursing and Health Professions 6 7%
Pharmacology, Toxicology and Pharmaceutical Science 4 4%
Biochemistry, Genetics and Molecular Biology 4 4%
Agricultural and Biological Sciences 4 4%
Other 9 10%
Unknown 16 18%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 April 2011.
All research outputs
#11,143,388
of 12,527,093 outputs
Outputs from Cochrane database of systematic reviews
#8,898
of 8,923 outputs
Outputs of similar age
#76,289
of 85,206 outputs
Outputs of similar age from Cochrane database of systematic reviews
#28
of 30 outputs
Altmetric has tracked 12,527,093 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,923 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.2. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 85,206 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.